Aspira Women’s Health (AWH) to Release Quarterly Earnings on Wednesday

Aspira Women’s Health (NASDAQ:AWH – Get Rating) will be issuing its quarterly earnings data after the market closes on Wednesday, March 22nd. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Aspira Women’s Health Stock Down 4.5 %

Aspira Women’s Health stock opened at $0.38 on Wednesday. The stock has a market capitalization of $47.60 million, a PE ratio of -1.41 and a beta of 2.96. Aspira Women’s Health has a 12 month low of $0.29 and a 12 month high of $1.26. The business has a 50 day simple moving average of $0.47 and a 200-day simple moving average of $0.40. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.15 and a quick ratio of 3.11.

Wall Street Analysts Forecast Growth

AWH has been the topic of a number of recent research reports. Cantor Fitzgerald lowered Aspira Women’s Health from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $3.00 to $2.00 in a research note on Friday, January 20th. StockNews.com began coverage on Aspira Women’s Health in a research note on Monday, December 12th. They issued a “sell” rating on the stock.

Institutional Investors Weigh In On Aspira Women’s Health

Several large investors have recently bought and sold shares of AWH. Atria Wealth Solutions Inc. acquired a new stake in Aspira Women’s Health during the 1st quarter worth approximately $49,000. JPMorgan Chase & Co. increased its stake in Aspira Women’s Health by 126.3% in the 1st quarter. JPMorgan Chase & Co. now owns 64,839 shares of the company’s stock valued at $67,000 after purchasing an additional 36,189 shares in the last quarter. Sawtooth Solutions LLC increased its stake in Aspira Women’s Health by 144.6% in the 1st quarter. Sawtooth Solutions LLC now owns 67,983 shares of the company’s stock valued at $71,000 after purchasing an additional 40,195 shares in the last quarter. Private Advisor Group LLC increased its stake in Aspira Women’s Health by 361.8% in the 1st quarter. Private Advisor Group LLC now owns 69,697 shares of the company’s stock valued at $73,000 after purchasing an additional 54,603 shares in the last quarter. Finally, Citadel Advisors LLC increased its stake in Aspira Women’s Health by 66.2% in the 2nd quarter. Citadel Advisors LLC now owns 252,841 shares of the company’s stock valued at $149,000 after purchasing an additional 100,727 shares in the last quarter. Hedge funds and other institutional investors own 10.63% of the company’s stock.

About Aspira Women’s Health

(Get Rating)

Aspira Women’s Health, Inc engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.